Inovio Pharmaceuticals Inc (INO)

8.01
0.02 0.25
NASDAQ : Health Care
Prev Close 7.99
Open 7.95
Day Low/High 7.87 / 8.21
52 Wk Low/High 4.50 / 11.69
Volume 732.72K
Avg Volume 1.22M
Exchange NASDAQ
Shares Outstanding 74.63M
Market Cap 647.76M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Inovio Provides Update On MedImmune Launch Of Combination Trial For HPV-associated Head & Neck Cancer

Phase 1b/2a study combines MedImmune's MEDI0457 (INO-3112), a DNA-based immunotherapy targeting HPV-associated cancer, and durvalumab, an immune checkpoint (PD-L1) inhibitor

Biotech Movers: Horizon, OncoMed, Inovio

Biotech Movers: Horizon, OncoMed, Inovio

Horizon Pharma, OncoMed Pharmaceuticals and Inovio Pharmaceuticals were among the biotech stock movers in early trading on Monday.

Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement For Glioblastoma Combination Therapy

Phase 1b/2a clinical trial will combine Regeneron's PD-1 inhibitor REGN2810 and Inovio's T cell activator INO-5401 and immune activator INO-9012 in brain cancer

Inovio Stock Rises on Positive Results From Ebola Vaccine Tests

Inovio Stock Rises on Positive Results From Ebola Vaccine Tests

The vaccine study showed that 95% of subjects generated an Ebola-specific antibody immune response.

Inovio And Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP's Ability to Induce Remission Of HIV Infection And End Lifetime Of Drug Therapy

Grant will fund therapeutic clinical studies testing PENNVAX-GP with INO-9012 (an IL-12 immune activator) alone and with the addition of a PD-1 checkpoint inhibitor

First Week Of INO November 17th Options Trading

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the November 17th expiration.

George Bickerstaff Elected To Inovio's Board Of Directors

Former Novartis CFO brings finance, fundraising and M&A experience to Inovio

Biotech Premarket Movers: Seres, PTC, Inovio

Biotech Premarket Movers: Seres, PTC, Inovio

Seres Therapeutics, PTC Therapeutics and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Williams-Sonoma Among 5 Earnings Plays That Could Squeeze the Shorts

Williams-Sonoma Among 5 Earnings Plays That Could Squeeze the Shorts

These heavily shorted stocks could get squeezed higher if they report positive earnings this week.

Interesting INO Put And Call Options For April 21st

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the April 21st expiration.

Inovio's SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential For Universal Cancer Immunotherapy

SynCon WT1 and PSMA antigens join hTERT in INO-5401, Inovio's cancer product planned for immuno-oncology combination study 

4 Biotech Stocks on the Move

4 Biotech Stocks on the Move

These four biotech stocks have been moving on some interesting news and clinical results.

Biotech Movers: Cempra Flys High On Phase Three Results

Biotech Movers: Cempra Flys High On Phase Three Results

Other movers include Incyte, Achillion and Inovio.

Hershey, Nvidia, Accenture, Cheniere Energy: 'Mad Money' Lightning Round

Hershey, Nvidia, Accenture, Cheniere Energy: 'Mad Money' Lightning Round

Jim Cramer is bullish on Hershey, Nvidia, Accenture, Cheniere Energy. He's bearish on Emerge Energy and Seaspan.

Stay Long, This Bull Is Strong: Cramer's 'Mad Money' Recap (Wednesday 2/15/17)

Stay Long, This Bull Is Strong: Cramer's 'Mad Money' Recap (Wednesday 2/15/17)

Don't get upended by the rhetoric. The transports are confirming, banks are solid, there's a genuine uptick in commerce and earnings are strong, says Jim Cramer.

Inovio And ApolloBio To Collaborate On Development And Commercialization Of HPV Pre-cancer Immunotherapy VGX-3100 In Greater China

Inovio to receive up to $50 million in upfront and near term payments and equity investment

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

Jim Cramer names a few of his favorite things: housing, bank, material and tech stocks, oil, copper and deregulation.

Chesapeake Energy, Comcast, Citigroup: 'Mad Money' Lightning Round

Chesapeake Energy, Comcast, Citigroup: 'Mad Money' Lightning Round

Jim Cramer is bullish on Chesapeake Energy and some bank stocks. But he's bearish on Inovio Pharmaceutical.